Skip to main content

Dechra Pharmaceuticals PLC (DPHAY)

OTC Markets (US) Healthcare Drug Manufacturers - GeneralView data quality →
38.6Poor

ValueMarkers Composite Index

Top 4%#43,091 of 44,707

DCF data not available

Piotroski
4/9
Neutral
Beneish
-2.60
Low Risk
Altman
4.92
Safe
DCF Value
-
N/A
ROIC
0.3%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Dechra Pharmaceuticals PLC (DPHAY) — VMCI valuation read

DPHAY screens at VMCI 39/100, a 11-point gap below the Healthcare sector median (50). For a mid-cap Dechra Pharmaceuticals PLC share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

DPHAY has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: DPHAY trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 0.2x leaves covenant headroom, which sets the rate-cycle exposure for Dechra Pharmaceuticals PLC.

DPHAY rose 2.8% over the trailing 7 days, with a +4.5% read on a 30-day basis.

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

CEO: Ian D. Page2,457 employeesGBwww.dechra.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in DPHAY’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.